Evidence map›Paper›PMID 34824052›Full record

Trial reportThe European respiratory journal2022

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.

Takeshi Ogo, Hiroto Shimokawahara, Hideyuki Kinoshita, Seiichiro Sakao, Kohtaro Abe, Satoaki Matoba, Hirohiko Motoki, Noriaki Takama, Junya Ako, Yasuhiro Ikeda and 12 more

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Review
  14. Review
  15. Review
  16. Clonal Hematopoiesis in Chronic Thromboembolic Pulmonary Hypertension.Journal of the American Heart Association · 2024
    Article
  17. Article
  18. Chronic thromboembolic pulmonary disease.The European respiratory journal · 2024
    Review
  19. Review
  20. Prevalence and Clinical Characteristics of HeterozygousJournal of the American Heart Association · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 18 institutions in 2 countries.

Takeshi OgoDivision of Advanced Medical Research in Pulmonary Hypertension, Division of Pulmonary Circulation, Dept of Cardiovascular Medicine, National Cerebral and Cardiovascular Centre, Suita, Japan tak@ncvc.go.jp.
Hiroto ShimokawaharaDept of Cardiology, National Hospital Organization Okayama Medical Centre, Okayama, Japan.
Hideyuki KinoshitaDept of Community Medicine Supporting System, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Seiichiro SakaoDept of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.ORCID 0000-0001-6719-1022
Kohtaro AbeDept of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Satoaki MatobaDept of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hirohiko MotokiDept of Cardiology, Shinshu University School of Medicine, Matsumoto, Japan.
Noriaki TakamaDept of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan.
Junya AkoDept of Cardiovascular Medicine, Kitasato University, Sagamihara, Japan.
Yasuhiro IkedaDept of Cardiology, Yamaguchi Prefectural Grand Medical Centre, Hofu, Japan.
Shuji JohoSecond Dept of Internal Medicine, University of Toyama, Toyama, Japan.
Hisataka MakiDept of Cardiology, The University of Tokyo Hospital, Tokyo, Japan.
Takahiro SaekiCardiovascular Medicine, National Hospital Organization Kanazawa Medical Centre, Kanazawa, Japan.
Teruyasu SuganoDept of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Ichizo TsujinoInternal Medicine I, Hokkaido University Hospital, Sapporo, Japan.
Koichiro YoshiokaDept of Cardiology, Tokai University School of Medicine, Isehara, Japan.
Naoki ShiotaClinical Development Dept, Nippon Shinyaku Co., Ltd, Kyoto, Japan.
Shinichi TanakaData Science Dept, Nippon Shinyaku Co., Ltd, Kyoto, Japan.
Chieko YamamotoClinical Development Dept, Nippon Shinyaku Co., Ltd, Kyoto, Japan.
Nobuhiro TanabeDept of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Koichiro TatsumiDept of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.ORCID 0000-0001-9484-7912
Study Group
Chiba University · JPNippon Shinyaku (Japan) · JPGunma University · JPHokkaido University Hospital · JPKanazawa Medical Center · JPKitasato University · JPKyoto Prefectural University of Medicine · JPKyoto University · JPKyushu University · JPLocal Initiatives Support Corporation · USNational Cerebral and Cardiovascular Center · JPNational Hospital Organization · JPShinshu University · JPTokai University · JPUniversity of Tokyo Hospital · JPUniversity of Toyama · JPYamaguchi Prefecture Central Hospital · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remain limited. Selexipag, an oral selective IP prostacyclin receptor agonist approved for pulmonary arterial hypertension, is a potential treatment option for CTEPH.

methodsIn this multicentre, randomised, double-blind, placebo-controlled study, 78 Japanese patients with inoperable CTEPH or persistent/recurrent pulmonary hypertension after pulmonary endarterectomy and/or balloon pulmonary angioplasty were randomly assigned to receive placebo or selexipag. The primary end-point was the change in pulmonary vascular resistance (PVR) from baseline to week 20. Secondary end-points were changes in other haemodynamic parameters: 6-min walk distance (6MWD), Borg dyspnoea scale score, World Health Organization (WHO) functional class, EuroQol five-dimension five-level tool and N-terminal pro-brain natriuretic peptide.

resultsThe change in PVR was -98.2±111.3 dyn·s·cm

conclusionSelexipag significantly improved PVR and other haemodynamic variables in patients with CTEPH, although exercise capacity remained unchanged. Further large-scale investigation is necessary to prove the role of selexipag in CTEPH.

Indexed as

Hypertension, PulmonaryPulmonary EmbolismAcetamidesAntihypertensive AgentsChronic DiseaseDyspneaHumansPyrazinesTreatment OutcomeAcetamidesAntihypertensive AgentsPyrazinesselexipag

Identifiers

PMID34824052
PMCPMC9260121
OpenAlexW3215969449

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.